EHA25 Virtual: Single-Agent Belantamab Mafodotin in Resistant Myeloma
Posted: Wednesday, June 24, 2020
For patients with relapsed or refractory multiple myeloma, treatment with the investigational monoclonal antibody belantamab mafodotin demonstrated positive activity and tolerability, according to the DREAMM-2 trial presented during the virtual edition of the 25th European Hematology Association (EHA) Virtual Congress (EHA25 Virtual; Abstract EP937). Single-agent belantamab mafodotin yielded similar objective response rates among patients with varying numbers of prior therapies, concluded Sagar Lonial, MD, of the Winship Cancer Institute at Emory University, Atlanta, and colleagues.
In this trial, the authors enrolled 97 patients with refractory or relapsed multiple myeloma who had received at least three prior therapies; they received 2.5 kg/mg or 3.4 mg/kg of belantamab mafodotin once every 3 weeks. Of the patients, 50 received at least seven prior therapies (52%).
For those who had received three to six prior therapies, the objective response rate was 32%, compared with 30% for those who had received at least seven prior therapies. Among the patients in receipt of between three and six prior therapies, 17% demonstrated at least a very good partial response, whereas 20% of those patients in receipt of at least seven prior therapies reported at least a very good partial response. The duration of response was not reached for either group of patients. The median progression-free survival was 2.9 months and 2.2 months for those who received between three and six prior therapies and for patients who received at least seven prior therapies.
The most common grade 3 or 4 adverse events for both subgroups were keratopathy, anemia, and decreased lymphocyte count. In both patient populations, adverse events were managed with dose delays and reductions, and discontinuation of treatment because of adverse events was rare.
Disclosure: For a full disclosure of the study authors, visit library.ehaweb.org.
